A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
← catalyst calendarSponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Other
Enrollment
24actual
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-24 | actual | When the study began enrolling |
| Primary completion | 2026-02-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-23 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: BG-71332
- Drug: Zanubrutinib — also filed as BGB-3111
- Drug: Sonrotoclax — also filed as BGB-11417
Primary outcomes
what the primary-completion date above is the date OFArea under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) for zanubrutinib
measured Predose and up to 72 hours post dose
Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) for sonrotoclax
measured Predose and up to 72 hours post dose
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t) for zanubrutinib
measured Predose and up to 72 hours post dose
Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t) for sonrotoclax
measured Predose and up to 72 hours post dose
Maximum observed plasma concentration (Cmax) of zanubrutinib
measured Predose and up to 72 hours post dose
Maximum observed plasma concentration (Cmax) of sonrotoclax
measured Predose and up to 72 hours post dose
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed